Ustekinumab or vedolizumab for refractory metastatic Crohn's disease?

Authors : Idris Kurt, Hüseyin Ahmet Tezel

Pages : 28-31

Doi:10.17941/agd.1465245

View : 29 | Download : 33

Publication Date : 2024-04-25

Article Type : Other Papers

Abstract :Metastatic Crohn\'s disease is a rare skin manifestation of Crohn’s disease. A variety of treatment options are available for this condition. But there is a lack of clarity regarding the treatment of resistant cases. There is ongoing debate as to which agent should be selected (vedolizumab or ustekinumab) in patients that are not responding to anti-tumor necrosis factor agents. This study identifies a unique patient who has developed a disease (metastatic Crohn\'s disease) under treatment with vedolizumab. Following treatment with ustekinumab, the patient regressed completely. Therefore, we recommend ustekinumab primarily in metastatic Crohn\'s disease.
Keywords : Metastatik Crohn hastalığı, ustekinumab, vedolizumab